Mersana To Focus Fully On Anti-Cancer ADCs With $27M Recapitalization
This article was originally published in The Pink Sheet Daily
Executive Summary
Nearly ready to out-license its remaining small molecule drug conjugate candidate, Mersana will focus exclusively on developing Fleximer-based antibody-drug conjugates through collaborations with Endo and future partners.
You may also be interested in...
Mersana Moves Into Antibody-Drug Conjugates With Endo Collaboration
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.
Mersana Teams With Teva To Develop Polymer Conjugate Cancer Drug
Linking fumagillin analogue with polymer should prevent CNS toxicities seen with previous fumagillin candidates.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.